Inhibition of thrombosis in melanoma allografts in mice by endogenous mast cell heparin

Thrombosis and Haemostasis

Volumn 90, Issue 2, 2003, Pages 351-360

  Samoszuk, Michael ^a   Corwin, Mark ^a   Yu, Hon ^a   Wang, Jun ^a   Nalcioglu, Orhan ^a   Su, Min Ying ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Coagulation; Heparin; Mast cell

Indexed keywords

AMINOCAPROIC ACID; ANTICOAGULANT PROTEIN; HEPARIN; HEPARIN ANTAGONIST; HEPARIN LYASE; PROTAMINE;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CANCER INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; GENE DISRUPTION; GENETIC CODE; HEMOSTASIS; HISTOCHEMISTRY; HISTOLOGY; HUMAN; IN VIVO STUDY; INHIBITION KINETICS; KNOCKOUT MOUSE; MAST CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOSIS; TRANSGENIC MOUSE; TUMOR GROWTH;

EID: 0041561130     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-02-0088     Document Type: Article

References (45)

1. Baish JW, Netti PA, Jain RK. Transmural coupling of fluid in microcirculatory network and interstitium in tumors. Microvasc Res 1997; 53: 128-41.
2. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endhothelial cells explain tumor vessel leakiness. Am. J. Pathol 2000; 156: 1363-80.
3. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 2000; 60: 4251-5.
4. Chang YS, Di Tomaso E, McDonald DM, et al. Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood. Proc Nat Acad Sci 2000; 97: 14608-13.
5. Siddiqui FA, Amirkhosravi A, Amaya M, et al. Purification and properties of human melanoma cell tissue factor. Clin Appl Thromb Hemos 2001; 7: 289-95.
6. Bromberg ME, Bailly MA, Konigsberg WH. Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor. Thromb. Haemost 2001; 86: 1210-4.
7. Amirkhosravi A, Biggerstaff JP, Warnes G, et al.. Determination of tumor cell procoagulant activity by sonoclot analysis in whole blood. Thromb Res 1996; 84: 323-32.
8. Wotukiewicz MZ, Zacharski LR, Memoli VA, et al. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990; 93: 516-21.
9. Bottasso B, Mari D, Coppola R, et al. Hypercoagulability and hyperfibrinolysis in patients with melanoma. Thromb Res 1996; 81: 345-52.
10. Dvorak AM, Mihm MC, Osage JE, Jr. Dvorak HF. Melanoma. An ultrastructural study of the host inflammatory and vascular responses. J Invest Dermatol 1980; 75: 388-93.
11. Demitsu T, Inoue T, Kakurai M, et al. Activation of mast cells within a tumor of angiosarcoma: Ultrastructural of five cases. J Dermatol 2002; 29: 280-9.
12. Reed JA, McNutt NS, Bogndany JK, Albino AP. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: Implications for melanoma progression. J Cutan Pathol 1996; 23: 495-505.
13. Duncan LM, Richards LA, Mihm MC, Jr. Increased mast cell density in invasive melanoma. J Cutan Pathol 1998; 25: 11-15.
14. Welker P, Schadendorf D, Artuc M, Grabbe J, Henz BM. Expression of SCF splice variants in human melanocytes and melanoma cell lines: Potential prognostic implications. Br J Cancer 2000; 82: 1453-8.
15. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: Value in the diagnosis of mast cell disorders. Hum Pathol 1998; 29: 498-504.
16. Starkey JR, Crowle PK, Taubenberger S. Mast-cell-defficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 1988; 42: 48-52.
17. Toth-Jakatics R, Jimi S, Takebayashi S, Kawamoto N. Cutaneous malignant melanoma: Correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Hum Pathol 2000; 31: 955-60.
18. Valent P, Baghestanian M, Bankl HC, et al.. New aspects in thrombosis research: Possible role of mast cells as profibrinolytic and anti-thrombotic cells. Thromb Haemost 2002; 87: 786-90.
19. Kauhanen P, Kovanen PT, Reunala T, Lassila R. Effects of skin mast cells on bleeding time and coagulation activation at the site of platelet plug formation. Thromb Haemost 1998; 79: 843-7.
20. Tchougounova E, Pejler G. Regulation of extravascular coagulation and fibrinolysis by heparin-dependent mast cell chymase. FASEB J 2001; 14: 2763-5.
21. Sillaber C, Baghestanian M, Bevec D, et al.. The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J Immunol 1999; 162: 1032-41.
22. Mallett SV, Cox DJA. Thromboelastography. Brit J Anaes 1992; 69: 307-13.
23. Kang YG, Martin DJ, Marquez J, et al. Intraoperative changes in blood coagulation and thromboelastographic monitoring in liver transplantation. Anesth Analg 1985; 64: 888-96.
24. Susic D, Mandal AK, Kentera D. Heparin lowers the blood pressure in hypertensive rats. Hypertension 1982; 4: 681-5.
25. Mandal AK, Lyden TW, Saklayen MG. Heparin lowers blood pressure: Biological and clinical perspectives. Kidney Int 1995; 47: 1017-22.
26. Stucker M, Horstmann I, Nuchel C, et al. Blood flow compared in benign melanocytic naevi, malignant melanomas and basal cell carcinomas. Clin Exp Dermatol 1999; 24: 107-11.
27. Su MY, Wang Z, Roth GM, et al. Pharmacokinetic changes induced by vasomodulators in kidneys, livers, muscles, and implanted tumors in rats as measured by dynamic Gd-DTPA-enhanced MRI. Magn Reson Med 1996; 36: 868-77.
28. Su MY, Muhler A, Lao X, Nalcioglu O. Tumor characterization with dynamic contrast-enhanced MRI using contrast agents of various molecular weights. Magn Reson Med 1998; 39: 259-69.
29. Lohse DL, Linhardt RJ. Purification and characterization of heparin lyases from Flavo-bacterium heparinum. J Bio Chem 1992; 267: 24347-55.
30. Su MY, Samoszuk MK, Wang J, Nalcioglu O. Assessment of protamine-induced thrombosis of tumor vessels for cancer therapy using dynamic contrast-enhanced MRI. NMR Biomed 2002; 15: 106-13.
31. Forsberg E, Pejler G, Ringvall M, et al. Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 1999; 400: 773-8.
32. Samoszuk M, Corwin MA. Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec). Int J Cancer (in press 2003).
33. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 245-51.
34. Yano H, Kinuta M, Tateishi H, et al. Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer 1999; 1: 26-32.
35. Elpek GO, Gelen T, Aksoy NH, et al. The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J Clin Pathol 2001; 54: 940-4.
36. Dethlefsen SM, Matsuura N, Zetter BR. Mast cell accumulation at sites of murine tumor implantation: Implications for angiogenesis and tumor metastasis. Invasion Metastasis 1994-1995; 14: 395-408.
37. Cooussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13: 1382-97.
38. Imada A, Shijubo N, Kojima H, Abe S. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 2000; 15: 1087-93.
39. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 2000; 88: 2686-92.
40. Thomas VA, Wheeless CJ, Stack MS, Johnson DA. Human mast cell tryptase fibrinogenolysis: Kinetics, anticoagulation mechanism, and cell adhesion disruption. Biochemistry 1998; 37: 2291-8.
41. Hallgren J, Estrada S, Karlson U, Alving K, Pejler G. Heparin antagonists are potent inhibitors of mast cell tryptase. Biochemistry 2001; 40: 7342-9.
42. Pejler G. Lactoferrin regulates the activity of heparin proteoglycan-bound mast cell chymase: Characterization of the binding of heparin to lactoferrin. Biochem J 1996; 320: 897-903.
43. Samoszuk MK, Min-Ying S, Ahmad N, Nalcioglu O. Selective thrombosis of tumor blood vessels in mammary adenocarcinoma implants in rats. Am J Pathol 2001; 159: 245-51.
44. Ornstein DL, Zacharski LR. Treatment of cancer with anticoagulants: Rationale in the treatment of melanoma. Int J Hematol 2001; 73: 157-61.
45. Desai UR, Wang H, Linhardt RJ. Substrate specificity of the heparin lyases from Flavobacterium heparinum. Arch Biochem Biophys 1993; 306: 461-8.